ACOG
Alpha Cognition Inc. Common StockNASDAQFinancial ServicesAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.20
P/S
9.42
EV/EBITDA
-1.44
DCF Value
$8.85
FCF Yield
-21.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.0%
Operating Margin
-220.9%
Net Margin
-202.2%
ROE
-48.9%
ROA
-25.9%
ROIC
-32.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.8M | $-6.9M | $-0.31 |
| FY 2025 | $10.2M | $-20.7M | $-1.17 |
| Q3 2025 | $2.8M | $-1.3M | $-0.08 |
| Q2 2025 | $1.7M | $-10.5M | $-0.65 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Financial Services
Industry
—
Country
CA
Exchange
NASDAQ
Beta
2.52
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.